Skip to content
Calculator
Evidence: HighPeptidomimeticFDA ApprovedPSMA PET tracerFDA-approved 2020Locametz · Illuccix · Gozellix

Gozetotide

The PSMA PET imaging agent that maps prostate cancer and picks patients for Pluvicto

Gozetotide, or PSMA-11, carries radioactive gallium-68 to prostate cancer cells that display PSMA, so a PET scan can show where the cancer is. First approved in 2020, it finds spread that CT and bone scans miss and is used to select patients for PSMA-targeted therapy.

Manufacturer's recommended dosing (FDA label): 111-259 MBq (3-7 mCi), Single injection, Slow intravenous injection Details ↓

Overview

What is it?

Finding exactly where prostate cancer has spread changes treatment: whether surgery or radiotherapy can cure it, where to aim radiation, and whether a patient can receive PSMA-targeted therapy. CT and bone scans miss small deposits. Gozetotide, developed as PSMA-11, binds prostate-specific membrane antigen on cancer cells and carries gallium-68, a positron emitter, so a PET scanner can see small clusters of PSMA-expressing cells.

Like vipivotide tetraxetan, it is built on a peptidomimetic glutamate-urea-lysine motif rather than a natural peptide chain, here joined to an HBED-CC chelator that holds the gallium. Gallium-68 decays within hours, so the tracer is prepared from a kit shortly before each scan. It is taken up in the liver, kidneys, spleen and salivary glands as well as in tumours; about 14% of the dose leaves in the urine within two hours.

Before first treatment, its value is ruling surgery in or out. In 775 men scheduled for prostatectomy at 12 centres in 11 countries, the scan found metastases in one in five and changed management to avoid surgery in about a quarter, and it beat MRI against surgical pathology for seminal vesicle and lymph node involvement. Its limit is size: in a German multicentre trial, node sensitivity was 40%, rising to 69% when deposits under 5 mm were set aside.

In the prostate itself it is about as sensitive as MRI and less specific. It matched fluorine-18 PSMA-1007 in a head-to-head study, and in men with a previous negative biopsy it predicted significant cancer more accurately than MRI. In a 2026 randomised trial, a scan-guided pathway avoided biopsy in about half of men with an equivocal MRI while finding a similar share of significant cancers.

In men whose cancer had returned, positive findings were confirmed by tissue in 84% of cases, and it can guide salvage radiotherapy. Newer tracers are already testing it: a copper-64 agent imaged a day later was positive in more than twice as many men with very low PSA. It was first approved in December 2020 for the UCLA and UCSF programmes that developed it, then as the kits Illuccix (2021), Locametz (2022) and Gozellix (2025).

The labels warn that images can be misread, because PSMA uptake is not specific to prostate cancer and also occurs in other tumours and benign conditions, and of radiation risk. Patients are asked to drink and to void before imaging, which starts 50 to 100 minutes after the injection.

24%
Prostatectomies avoided after staging
775 men, 12 centres · PMID 41233146
111-259 MBq
Labelled adult activity
Locametz and Illuccix labels
50-100 min
Injection to imaging
Label 2.7
Science

Mechanism of Action

Gozetotide carries gallium-68 to prostate-specific membrane antigen, so PSMA-expressing cancer shows on a PET scan.

🎯

PSMA binding

A glutamate-urea-lysine motif binds prostate-specific membrane antigen on prostate cancer cells.

📡

Positron imaging

The HBED-CC chelator holds gallium-68, whose positrons a PET scanner detects.

🚰

Distribution and clearance

Taken up mainly in liver (15%), kidneys (7%), spleen and salivary glands; 14% of the dose is in the urine within 2 hours (Locametz label 12.3).

Evidence

Published Research

The studies behind gozetotide, read from their PubMed abstracts.

Human2025

Pharmacokinetics and radiation dose

In Japanese patients given 111 to 259 MBq before lutetium-177 PSMA-617 therapy, the tracer cleared from the blood in two phases with a terminal half-life of about 3.9 hours; the kidneys received the largest absorbed dose, and the effective dose was 0.030 mSv per MBq.

PMID: 40638023
Human2019

Recurrent cancer, 635 men

In men whose cancer had returned after prostatectomy or radiotherapy, the scan located recurrence in 75%, rising from 38% at PSA below 0.5 ng/mL to 97% at 5 ng/mL or more. Positive findings were confirmed by tissue in 84%, and no serious adverse events were linked to the tracer.

PMID: 30920593
Human2026

Replacing some biopsies

In 660 men with high-risk features but an equivocal or non-suspicious MRI, a PSMA PET-guided pathway found clinically significant cancer in 12% against 16% with systematic biopsy, meeting non-inferiority, and avoided biopsy in 49%.

PMID: 42269655
Human2026

EMPIRE-2: guiding salvage radiotherapy

In 140 men with recurrence after prostatectomy, PET-guided radiotherapy with dose escalation gave 87% two-year event-free survival against 80% in the earlier EMPIRE-1 comparison cohort.

PMID: 41412908
Human2026

EMPIRE-2: changes to radiotherapy plans

Scans changed salvage radiotherapy decisions in 42% of men imaged with PSMA-11 and 29% with fluciclovine, with no clear difference between the tracers.

PMID: 42377125
Human2024

Predicting benefit in VISION

In 826 men from the VISION trial, the average PSMA uptake across all tumours on the baseline scan best predicted benefit from lutetium-177 PSMA-617: each one-unit rise cut the risk of progression by 12% and of death by 10%, though benefit was seen at every uptake level.

PMID: 39162634
Human2026

Staging before prostatectomy, 12 centres

In an international study of 775 men with unfavourable intermediate- or high-risk cancer scheduled for prostatectomy, the PSMA-11 scan found metastases in 20.4% and changed management to avoid surgery in 24.0%. Against surgical pathology, it was more accurate than MRI for seminal vesicle invasion (90.1% against 57.3%) and lymph nodes (91.1% against 69.7%), though 4.5% were wrongly staged node-negative.

PMID: 41233146
Human2026

DKTK phase 1/2 in new high-risk cancer

In 173 men staged before treatment, sensitivity for the tumour in the prostate was 97%, but for lymph node spread it was 40% with 99% specificity; excluding deposits under 5 mm, the size limit of PET, raised node sensitivity to 69%. No serious adverse events occurred.

PMID: 41240091
Human2026

Against fluorine-18 PSMA-1007 and MRI

In 50 men checked against prostate pathology, gallium-68 PSMA-11 and fluorine-18 PSMA-1007 found clinically significant cancer in 100% and 98%, with no significant difference between them; both were more sensitive than MRI, which was more specific.

PMID: 42762314
Human2026

After a negative biopsy

In men with persistent suspicion of prostate cancer after a negative biopsy, a PSMA-11 PET score was more accurate than MRI PI-RADS for clinically significant cancer (92% against 83%).

PMID: 41784782
Human2026

Against a copper-64 PSMA tracer

In 50 men with low-PSA recurrence after prostatectomy, a 24-hour copper-64 SAR-bisPSMA scan was positive in 78% against 36% for gallium-68 PSMA-11, and management changed between scans in 44%. The newer tracer is investigational.

PMID: 41904043
Human2026

Against a SPECT tracer for staging: phase 2

In men with newly diagnosed high-risk prostate cancer scanned three ways, gallium-68 PSMA-11 PET found more lymph-node lesions than the technetium-99m MIP-1404 SPECT tracer, which as judged against PET detected 81% of node and 85% of bone metastases; treatment decisions agreed in 30 of 33 patients.

PMID: 42489957
Human2026

Pharmacokinetics and radiation dose in Chinese patients

In seven Chinese men with progressive metastatic castration-resistant prostate cancer, gallium-68 PSMA-11 cleared from blood with an effective half-life of about 1.3 hours, the kidneys, bladder wall and tear glands received the highest doses, and the effective dose was about 4.2 mSv per scan.

PMID: 41689461
Dosing

Dosing Data

Gozetotide is a single intravenous diagnostic dose prepared from a kit in a nuclear medicine department; whole-body PET follows 50 to 100 minutes later.

Radioactive diagnostic agent given only by nuclear medicine staff; the activity is measured before injection.
ProtocolDoseFrequencyDurationRoute
Label: PSMA PET in men with prostate cancer (Locametz) Approved labelLocametz (kit for the preparation of gallium Ga 68 gozetotide injection) US prescribing information (Novartis; DailyMed set 8683b06e, effective January 15, 2026)111-259 MBq (3-7 mCi)Single injectionImaging 50-100 minutes after injectionSlow intravenous injection
Label: PSMA PET in men with prostate cancer (Illuccix) Approved labelIlluccix (kit for the preparation of gallium Ga 68 gozetotide injection) US prescribing information (Telix; DailyMed set d4643b31, version 18, effective June 25, 2026)111-259 MBq (3-7 mCi)Single injectionImaging 50-100 minutes after injection; delayed imaging up to about 4 hours on long axial field-of-view PET/CTIntravenous bolus

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Measured in becquerels
Gozetotide is dosed by radioactivity, 111 to 259 MBq, measured in a dose calibrator by nuclear medicine staff; no reconstitution maths applies.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved products, as their labels describe them:

  • Locametz (kit for the preparation of gallium ga 68 gozetotide injection): Eckert & Ziegler GalliaPharm (Ge 68/Ga 68) generator IRE ELiT Galli Eo (Ge 68/Ga 68) generator After radiolabeling with gallium-68, each vial contains a sterile, clear, colorless solution free from particulate matter of gallium Ga 68 gozetotide at an activity of up to 2,590 MBq (70 mCi) in up to 10 mL at calibration date and time. Forms the label lists: multiple-dose vials.
  • Illuccix (kit for the preparation of gallium ga 68 gozetotide injection): How Supplied ILLUCCIX (kit for the preparation of gallium Ga 68 gozetotide injection) is available in two different configurations. Forms the label lists: multiple-dose vials.

Source: Locametz (kit for the preparation of gallium ga 68 gozetotide injection) label, section 3 (DailyMed version 1, effective January 15, 2026); Illuccix (kit for the preparation of gallium ga 68 gozetotide injection) label, section 16 (DailyMed version 18, effective June 25, 2026).

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Gozetotide is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.

This page's dosing note: “Gozetotide is dosed by radioactivity, 111 to 259 MBq, measured in a dose calibrator by nuclear medicine staff; no reconstitution maths applies.”

Its label says: “Radiopharmaceuticals should be used by or under the control of health care providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the governmental agency authorized to license the use of radionuclides.”

Source: this page's own note in Dosing Data below; Locametz (kit for the preparation of gallium ga 68 gozetotide injection) label, section 2 (DailyMed version 1, effective January 15, 2026); the amount of each dose row in Dosing Data below.

Storage before and after mixing

Before mixing or first use: “Storage and Handling Before radiolabeling, store at 2°C to 25°C (36°F to 77°F).” “After radiolabeling, store upright with an appropriate lead shielding to protect from radiation, below 30°C (86°F).” “Do not freeze.”

After mixing or first use: the label sentences we read say nothing separate about this.

Source: Locametz (kit for the preparation of gallium ga 68 gozetotide injection) label, sections 16 and 2 (DailyMed version 1, effective January 15, 2026).

How it is taken

As the approved label gives it: Slow intravenous injection (Single injection; Label: PSMA PET in men with prostate cancer (Locametz)); Intravenous bolus (Single injection; Label: PSMA PET in men with prostate cancer (Illuccix)).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Label: PSMA PET in men with prostate cancer (Locametz): Imaging 50-100 minutes after injection; Label: PSMA PET in men with prostate cancer (Illuccix): Imaging 50-100 minutes after injection; delayed imaging up to about 4 hours on long axial field-of-view PET/CT.

When effects appear: unknown; no source on this page gives a time to effect for Gozetotide. Results reported in the studies are under Published Research.

Source: Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: No serious adverse events linked to the tracer in the 635-patient recurrence study; Radiation exposure: an effective dose of 0.030 mSv per MBq in the pharmacokinetic study. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Gozetotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies and labels”).

Interactions

  • androgen deprivation therapy and androgen-receptor antagonists: can change gozetotide uptake in prostate cancer; effect on scan performance not established

Every peptide's record, with its source: the interaction matrix.

Source: Novartis. LOCAMETZ (kit for gallium Ga 68 gozetotide) US prescribing information, section 7. DailyMed version of January 15, 2026, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Gozetotide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (First approved in the US on December 1, 2020 as gallium Ga 68 PSMA-11 (gozetotide) for two academic producers, UCLA (NDA 212642) and UCSF (NDA 212643)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies and labels.

● No serious adverse events linked to the tracer in the 635-patient recurrence study
● Radiation exposure: an effective dose of 0.030 mSv per MBq in the pharmacokinetic study

Contraindications & Cautions

Warnings from the Locametz (DailyMed, effective January 15, 2026) and Illuccix (effective June 15, 2026) labels.

● Risk for misinterpretation: uptake is not specific to prostate cancer and may be seen in other cancers and benign conditions
● Radiation risk: hydration and frequent voiding to reduce exposure
Questions

Frequently Asked Questions

?What is a PSMA PET scan?

A scan that uses a PSMA-binding tracer, such as gallium Ga 68 gozetotide, to show where prostate cancer cells are in the body. It finds spread that CT and bone scans often miss.

?How does it relate to Pluvicto?

Both bind PSMA. Gozetotide carries an imaging isotope and is used to confirm PSMA-positive disease; Pluvicto carries a treatment isotope and is given to patients whose scans show the target.

?Is the scan specific to prostate cancer?

No. Its labels warn that PSMA uptake also occurs in other cancers and some benign conditions, so images need careful interpretation.

?What are the scan's limits?

Size, mainly. Deposits under about 5 mm are often missed: in one multicentre trial, lymph node sensitivity was 40% before excluding them and 69% after.

?How is the scan done?

An intravenous injection of 111 to 259 MBq, then whole-body PET 50 to 100 minutes later; patients drink fluids and empty the bladder before imaging.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): gallium Ga 68 gozetotide, NDA 212642 (UCLA) and NDA 212643 (UCSF), approved December 1, 2020; ILLUCCIX NDA 214032 (December 17, 2021); LOCAMETZ NDA 215841 (March 23, 2022); GOZELLIX NDA 219592 (March 20, 2025). Read October 3, 2026.
  2. [fda-pi] FDA. Locametz (kit for gallium Ga 68 gozetotide) US prescribing information (DailyMed set 8683b06e-4901-4526-89ad-23a8fe2d1331, version 1, effective January 15, 2026). Read October 3, 2026.
  3. [fda-pi] FDA. Illuccix (kit for gallium Ga 68 gozetotide) US prescribing information (DailyMed set d4643b31-9b4f-673f-e053-2a95a90a559d, version 18, effective June 25, 2026). Read October 3, 2026 (version and date updated to the current SPL, October 27, 2026).
  4. [clinical-trial] Takano S, et al. "Pharmacokinetics and dosimetry of [(177)Lu]Lu-PSMA-617 and [(68)Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC." Ann Nucl Med, 2025;39(11):1201-1212. PMID: 40638023.
  5. [clinical-trial] Fendler WP, et al. "Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial." JAMA Oncol, 2019;5(6):856-863. PMID: 30920593.
  6. [clinical-trial] Buteau JP, et al. "Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial." Lancet Oncol, 2026;27(7):839-848. PMID: 42269655.
  7. [clinical-trial] Jani AB, et al. "[(18)F]-Fluciclovine or [(68)Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial." Eur Urol, 2026;89(4):368-377. PMID: 41412908.
  8. [clinical-trial] Abiodun-Ojo OA, et al. "(18)F-Fluciclovine or (68)Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial." Radiology, 2026;319(3):e251874. PMID: 42377125.
  9. [pubmed] Kuo PH, et al. "Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial)." Radiology, 2024;312(2):e233460. PMID: 39162634.
  10. [pubmed] Cerci JJ, et al. "(68)Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study." J Nucl Med, 2026;67(1):67-70. PMID: 41233146.
  11. [pubmed] Giesel FL, et al. "The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 (68)Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management." Eur J Nucl Med Mol Imaging, 2026;53(5):2994-3006. PMID: 41240091.
  12. [pubmed] Gossili F, et al. "Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study." Eur J Nucl Med Mol Imaging, 2026. PMID: 42762314.
  13. [pubmed] Lopci E, et al. "[(68)Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)." Eur J Nucl Med Mol Imaging, 2026;53(7):4424-4435. PMID: 41784782.
  14. [pubmed] Khan S, et al. "Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)." Eur Urol, 2026;89(6):512-520. PMID: 41904043.
  15. [fda-pi] Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) US prescribing information (Novartis; DailyMed set 8683b06e, version 1, effective January 15, 2026), sections 2.2-2.7 and 12.3; read through openFDA October 6, 2026.
  16. [pubmed] Saudi A, et al. "Head-to-head comparison of (99m)Tc-MIP-1404 CZT SPECT/CT and (68)Ga/PSMA-11 PET/CT for primary staging of high-risk prostate cancer: a phase II study." EJNMMI Res, 2026;16(1). PMID: 42489957.
  17. [pubmed] Fan W, et al. "Pharmacokinetics and Dosimetry of [(68)Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study." Cancer Biother Radiopharm, 2026;41(5):430-438. PMID: 41689461.

Sources & Citations

Studies were read from their PubMed abstracts; the Locametz and Illuccix labels from DailyMed through openFDA, read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-16